Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4201-4206

  Hazama, Shoichi ^a   Takenouchi, Hiroko ^a   Tsunedomi, Ryouichi ^a   Iida, Michihisa ^a   Suzuki, Nobuaki ^a   Iizuka, Norio ^a   Inoue, Yuka ^a   Sakamoto, Kazuhiko ^a   Nakao, Mitsuhiro ^a   Shindo, Yoshitaro ^a   Kanekiyo, Shinsuke ^a   Tokumitsu, Yukio ^a   Yoshimura, Kiyoshi ^a   Maeda, Noriko ^a   Maeda, Kazunari ^a   Maeda, Yoshinari ^a   Matsui, Hiroto ^a   Yoshino, Shigefumi ^a   Nakamura, Yusuke ^b   Fujita, Yusuke ^c   Hamamoto, Yoshihiko ^c   Okamoto, Masato ^d   Fujita, Tomonobu ^d   Kawakami, Yutaka ^d   Oka, Masaaki ^a   more..

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

^c YAMAGUCHI UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Peptide vaccine; Predictive biomarker; Prognosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 6; KOC 1 PEPTIDE VACCINE; PEPTIDE VACCINE; RNF 43 721 PEPTIDE VACCINE; TOMM 34 299 PEPTIDE VACCINE; UNCLASSIFIED DRUG; VEGFR 1 1084 PEPTIDE VACCINE; VEGFR 2 169 PEPTIDE VACCINE; EPITOPE; PEPTIDE;

AMERICAN; ARTICLE; BLOOD CELL COUNT; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; RECOMMENDED DRUG DOSE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; BLOOD; COLORECTAL TUMOR; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; MORTALITY; PREDICTIVE BIOMARKER; PROGNOSIS; VACCINATION;

COLORECTAL CANCER; PEPTIDE VACCINE; PREDICTIVE BIOMARKER; PROGNOSIS;

C-REACTIVE PROTEIN; CANCER VACCINES; COLORECTAL NEOPLASMS; EPITOPES; HUMANS; INTERLEUKIN-6; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84908672347     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
2. Boon T and van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725-729, 1996.
3. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137, 2001.
4. Yagyu R, Furukawa Y, Lin YM, Shimokawa T, Yamamura T and Nakamura Y: A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer. Int J Oncol 25: 1343-1348, 2004.
5. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol 29: 381-386, 2006.
6. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K and Nakamura Y: Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anticancer drugs. Oncogene 22: 2192-2205, 2003.
7. Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L and Chen L: Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett 6: 740-744, 2013.
8. U.S. Department of Health and Human Services, Food and Drug Administration: Guidance for Industry. Clinical Considerations for Therapeutic Cancer Vaccines. October 2011, http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pd.
9. Nagorsen D and Thiel E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12: 3064-3069, 2006.
10. Hazama S, Nakamura Y, Takenouchi H, Suzuki N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K, Shinozaki H, Kamiya A, Furukawa H and Oka M: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer: safety, immunological response, and clinical outcome. J Transl Med 12: 63, 2014.
11. Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y and Tahara H: Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res 10: 8577-8586, 2004.
12. Suda T, Tsunoda T, Daigo Y, Nakamura Y and Tahara H: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 98: 1803-1808, 2007.
13. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M and Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12: 5841-5849, 2006.
14. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 65: 4939-4946, 2005.
15. Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K and Oka M: A phase i clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37: 36-42, 2014.
16. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP and Maccalli C: Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 17: 3064-3076, 2011.
17. Whiteside TL: Immune responses to cancer: Are they potential biomarkers of prognosis? Front Oncol 3: 107, 2013.
18. Fisher DT, Appenheimer MM and Evans SS: The two faces of IL6 in the tumor microenvironment. Semin Immunol 26: 38-47, 2014.
19. Lesina M, Wormann SM, Neuhofer P, Song L and Algul H: Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol 26 : 80-87, 2014.
20. Scheller J, Garbers C and Rose-John S: Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 26: 2-12, 2014.
21. Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J and Kurzrock R.: A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 20: 1-13, 2014.